Napo Pharmaceuticals, Inc., (LSE: NAPL and NAPU) is pleased to announce the positive results of a successfully completed Phase 2 trial for CRO-ID (crofelemer for the treatment of acute adult infectious diarrhea) conducted by its partner, Glenmark Pharmaceuticals Limited (BSE: Glenmark).

More: continued here

This entry was posted on Friday, April 11th, 2008 at 1:04 pm and is filed under GastroIntestinal / Gastroentorology. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.